Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: Grantcw who wrote (2913)	10/12/2011 11:56:07 AM
From: richardred	Read Replies (2) \| Respond to of 7243

Grant it's my biggest disaster this year. I've already doubled down my position. The attraction to me is the orphan drug status of KRYSTEXXA (patent protection). I've lowered my speculative appeal that it might get acquired anytime soon. I'll say it's a 5 down from a 8 when I first bought in. I knew going in it would be at least a year to see how well the drug was selling. I not an expert in Pharma, but I would still think there are attractions to a would be buyer. Those being new testing for additional indications and applications. I still think they are looking for a partner for European rights of KRYSTEXXA. What we also know. Over 24 million shares will eventually have to be covered sometime. Maybe a hope and a prayer for us still.